Rociletinib regulatory update

Clovis said FDA notified the biotech that the agency plans to issue a complete response letter for an NDA for rociletinib on or before the June 28 PDUFA date. Clovis said it

Read the full 323 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE